Safety of crizotinib in 892 Japanese ALK-positive advanced NSCLC patients: Interim report of post-marketing surveillance

被引：0
|
作者：
Okamoto, Isamu [1 ]
Nakagawa, Kazuhiko [2 ]
Ohe, Yuichiro [3 ]
Ueno, Naomi [4 ]
Banno, Shigeo [4 ]
Endo, Yutaka [4 ]
Ohki, Emiko [4 ]
Gemma, Akihiko [5 ]
机构：
[1] Kyusyu Univ Hosp, Ctr Clin & Transrat Res, Fukuoka, Japan
[2] Kinki Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[3] Natl Canc Ctr, Dept Resp Med, Tokyo, Japan
[4] Pfizer Japan Inc, Tokyo, Japan
[5] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo 113, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY12-3
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND TOXICITY OF CRIZOTINIB FOR PATIENTS WITH ALK-POSITIVE ADVANCED NSCLC
    Asao, T.
    Honma, Y.
    Suina, K.
    Muraki, K.
    Shukuya, T.
    Ohashi, R.
    Koyama, R.
    Shimada, N.
    Sakuraba, S.
    Takahashi, K.
    ANNALS OF ONCOLOGY, 2013, 24
  • [2] Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese Patients
    Cui, Shaohua
    Zhao, Yizhuo
    Gu, Aiqin
    Ge, Xiaoxiao
    Song, Yanyan
    Zhang, Wei
    Lou, Yuqing
    Dong, Lili
    Han, Baohui
    Jiang, Liyan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
  • [3] A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
    Dikopf, Alana
    Wood, Kevin
    Salgia, Ravi
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 485 - 493
  • [4] Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC
    Camidge, D. Ross
    Kim, Elizabeth E.
    Usari, Tiziana
    Polli, Anna
    Lewis, Iona
    Wilner, Keith D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1077 - 1085
  • [5] Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings
    Ueno, Naomi
    Banno, Shigeo
    Endo, Yutaka
    Tamura, Motoko
    Sugaya, Katsuko
    Hashigaki, Satoshi
    Ohki, Emiko
    Yoshimura, Akinobu
    Gemma, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 676 - 686
  • [6] Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data
    Mimori, Tsuneyo
    Harigai, Masayoshi
    Atsumi, Tatsuya
    Kuwana, Masataka
    Takei, Syuji
    Tamura, Naoto
    Fujii, Takao
    Matsuno, Hiroaki
    Momohara, Shigeki
    Yamamoto, Kazuhiko
    Kokubo, Takeshi
    Endo, Yutaka
    Sugiyama, Naonobu
    Hirose, Tomohiro
    Morishima, Yosuke
    Yoshii, Noritoshi
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [7] POST-MARKETING SURVEILLANCE OF TOFACITINIB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM REPORT OF SAFETY DATA
    Tamura, N.
    Kuwana, M.
    Atsumi, T.
    Takei, S.
    Harigai, M.
    Fujii, T.
    Matsuno, H.
    Mimori, T.
    Momohara, S.
    Yamamoto, K.
    Nomura, K.
    Endo, Y.
    Sugiyama, N.
    Hirose, T.
    Morishima, Y.
    Yoshii, N.
    Takagi, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1408 - 1408
  • [8] Crizotinib Outcomes in ALK-Positive Advanced NSCLC Patients with Brain Metastases
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S376 - S377
  • [9] POST-MARKETING SURVEILLANCE OF TOFACITINIB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM REPORT OF SAFETY DATA
    Mimori, T.
    Harigai, M.
    Atsumi, T.
    Kuwana, M.
    Takei, S.
    Tamura, N.
    Fuji, T.
    Matsuno, H.
    Momohara, S.
    Yamamoto, K.
    Kokubo, T.
    Endo, Y.
    Sugiyama, N.
    Hirose, T.
    Morishima, Y.
    Yoshii, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1200 - 1201
  • [10] A JAPANESE POST-MARKETING SURVEILLANCE OF REGORAFENIB IN COLORECTAL CANCER PATIENTS: INTERIM REPORT
    Satoh, Taroh
    Yamazaki, Naoya
    Takikawa, Hajime
    Ito, Hideyuki
    Ito, Yuichiro
    Sakaguchi, Toshiaki
    Yamada, Takashi
    Muro, Kei
    Sugihara, Kenichi
    ANNALS OF ONCOLOGY, 2014, 25
12345